Defending the rationale for the two-tailed test in clinical research

Circulation

Volumn 105, Issue 25, 2002, Pages 3062-3065

  Moyé, Lemuel A ^a   Tita, Alan T N ^a  

^a RAS Building E815 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL RESEARCH; HEALTH CARE; HEALTH CARE PERSONNEL; MEDICAL ETHICS; PRIORITY JOURNAL; REVIEW; STATISTICS;

CARDIOLOGY; CLINICAL TRIALS; ETHICS, CLINICAL; HUMANS; KNOWLEDGE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SAMPLE SIZE; STATISTICS;

EID: 0037173109     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000018283.15527.97     Document Type: Review

References (15)

1. The use of one-sided tests in drug trials: An FDA advisory committee member's perspective
2. One and two-sided tests of significance: One-sided tests should be used more often
3. An alternative to the use of two-sided tests in clinical trials
4. Statistics notes: One and two-sided tests of significance
5. The ethics of sample size: Two-sided testing and one-sided thinking
6. Random research
7. P-value interpretation, and alpha allocation in clinical trials
8. Monitoring boundaries for adverse effects in long-term clinical trials
9. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
10. The Cardiac Arrhythmia Suppression Trial: Casting ventricular arrhythmia suppression in a new light
11. One-sided and two-sided tests and p-values
12. Effects of vesnarinone on morbidity and mortality in patients with heart failure
13. A dose-dependent increase in mortality seen with vesnarinone among patients with severe heart failure